Clifford J. Rosen
Maine Medical Center
717 Papers
6.3K Citations
Clifford J. Rosen is an academic researcher from Maine Medical Center. The author has contributed to research in topics: Osteoporosis & Bone density. The author has an hindex of 111, co-authored 655 publications. Previous affiliations of Clifford J. Rosen include Veterans Health Administration & Thomas Jefferson University.
Chat about Author
Papers
Diet and gene interactions influence the skeletal response to polyunsaturated fatty acids.
TL;DR: Compared to safflower oil, fish oil (high ratio omega-3/-6) prevents weight gain, bone loss, and changes in trabecular microarchitecture in the spine with age, and these beneficial effects are absent in mice with polymorphisms in the Pparγ gene (6T), supporting the tenet that the actions of n-3 fatty acids on bone microstructure are likely to be genotype dependent.
29
Biochemical markers of bone turnover: A look at laboratory tests that reflect bone status
TL;DR: Tests for biochemical markers serving as markers for monitoring bone loss, bone reformation, and the effectiveness of therapy in patients with osteoporosis may prove preferable to densitometry in some settings or for some patients.
29
VITAL Signs for Dietary Supplementation to Prevent Cancer and Heart Disease
John F. Keaney,Clifford J. Rosen +1 more
TL;DR: The results from the Vitamin D and Omega-3 Trial (VITAL), a randomized, double-blind, placebo-controlled trial (with a two-by-two factorial design), show that any long-term health benefits from these products remain in doubt.
28
Emerging anabolic treatments for osteoporosis.
TL;DR: There is emerging evidence that anabolic agents can reduce subsequent fracture risk and the two most promising agents, parathyroid hormone (PTH and GH/IGF-I, act to increase osteoblast mediated bone formation.
28
Romosozumab - Promising or Practice Changing?
TL;DR: Among patients with osteoporosis who have had a fracture and are then prescribed bisphosphonates, 70% are nonadherent within a year, and Denosumab, another antiresorptive agent with proven efficacy, is rarely associated with atypical fractures and requires that patients continue to receive therapy indefinitely.
28